Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud's phenomenon

Ann Intern Med. 1981 Apr;94(4 pt 1):482-4. doi: 10.7326/0003-4819-94-4-482.

Abstract

Von Willebrand factor activity and factor VIII/von Willebrand factor (fVIII/vWf) antigen concentrations were evaluated in 17 patients with scleroderma, nine patients with Raynaud's phenomenon, and eight control volunteers. Higher circulating levels of both activities were seen: von Willebrand factor, 374% +/- 40% (percent of control values) in scleroderma patients, 502% +/- 104% in patients with Raynaud's phenomenon and 102% +/- 6% in control subjects (p less than 0.005, scleroderma versus control): fVIII/vWf antigen, 255% +/- 24% in scleroderma patients; 271% +/- 46% in patients with Raynaud's phenomenon, and 99% +/- 4% in control subjects (p less than 0.005, scleroderma versus control). Because endothelial cells synthesize and secrete both substances, the role of endothelial injury in vitro was investigated. Wound injury induced a 344% +/- 33% increase in von Willebrand factor and a 115% +/- 5% increases in fVIII/vWf antigen; cold injury induced 644% +/- 66% and 150% +/- 10% increases, and cytotoxic endothelial injury induced 1055% +/- 83% and 185% +/- 20% increases. In five patients with scleroderma, cold exposure led to a further increase in both activities. The observed increase of both activities in scleroderma and Raynaud's phenomenon may reflect in-vivo endothelial injury and regeneration in these related conditions.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Antigens / analysis
  • Blood Coagulation Factors / analysis*
  • Endothelium / pathology
  • Factor VIII / metabolism*
  • Female
  • Humans
  • Male
  • Raynaud Disease / blood*
  • Scleroderma, Systemic / blood*
  • Scleroderma, Systemic / pathology
  • von Willebrand Factor / analysis*

Substances

  • Antigens
  • Blood Coagulation Factors
  • von Willebrand Factor
  • Factor VIII